← Back to Calendar

Cogent Biosciences Q1 2026 Earnings

Cogent Biosciences · $COGT

Standard Review Earnings

PDUFA Date

May 5, 2026

Time Remaining

42 days

Review Type

Standard (10 mo)

Indication

Q1 2026 earnings + bezuclastinib APEX data timeline

Key Notes

Q1 2026 earnings expected May 5, 2026. Critical update on bezuclastinib APEX Phase 2 in advanced systemic mastocytosis — data readout expected mid-2026 (potential ASCO/EHA presentation).

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar